Date:1/29/2013

ties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

---

Contacts:Media RelationsInvestor RelationsSarah ConnorsKristen GalfettiTel.: 617.252.7639Tel.: 1 908 981.5560Sarah.Connors@sanofi.comir@sanofi.com

'/>"/>

SOURCE Sanofi Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
2. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
3. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
6. Sanofi Pasteur to add 2D barcode to six more vaccines
7. Sanofi US Launches Collaborate Activate Innovation Challenge
8. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
9. New Website IVT Network Launches Today for Validation and Compliance Professionals
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. Sequent Medical, Inc. Launches VIA Microcatheter